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Abstract: The description of the allosteric modification of receptors to affect changes in their function requires a model that considers 
the effects of the modulator on both agonist affinity and efficacy. A model is presented which describes changes in affinity in terms of the 
constant  (ratio of affinity in the presence vs the absence of modulator) and also the constant  (ratio of intrinsic efficacy of the agonist 
in the presence vs absence of modulator). This allows independent effects of both affinity and efficacy and allows the modeling of any 
change in the dose-response curve to an agonist after treatment with modulator. Examples are given where this type of model can predict 
effects of modulators that reduce efficacy but actually increase affinity of agonist (i.e. ifenprodil) and also of modulators that block the 
action of some agonists (the CXCR4 agonist SDF-1 by the antagonist AMD3100) but not others for the same receptor (SDF-1 peptide 
fragments RSVM and ASLW). 
‘All models are wrong…but some are useful…’ 
anonymous environmental scientist 
INTRODUCTION 
  Heptahelical (also referred to as seven transmembrane, 7TM, 
G-protein coupled) receptors are nature’s prototype allosteric pro-
tein. They are designed to bind neurotransmitters, hormones, auta-
coids and other signaling molecules in one loci and transmit the 
information contained therein to another loci where other cellular 
partners such as G-proteins or -arrestin interact. This information 
is transmitted as a change in the tertiary shape of the receptor to 
alter the affinity of these cellular partners after ligand binding. In 
fact, the change in rate of binding of G-proteins has been directly 
measured using plasmon-waveguide resonance spectroscopy. Spe-
cifically, studies on the -opioid receptor show that agonists and 
inverse agonists produce 50-fold changes in affinity for the G-
protein subunit G0 [1], all this from the binding of a molecule 
some distance away from the receptor/G-protein site of interaction. 
This paper will discuss the allosteric nature of these receptors, the 
mechanisms by which small molecules can influence large protein 
tertiary structure, and the models used to describe and predict these 
effects.  
SYSTEM CAPABILITY 
  The first question is to consider what heptahelical receptors are 
capable of as they interact with various components of the cell. One 
of the key factors to consider is that, like all proteins, receptors can 
adopt numerous tertiary conformations. Since they also interact 
with a number of other cellular proteins, they have the capability of 
functioning as sophisticated signaling processing units. The idea 
that receptors form numerous conformations according to thermal 
energy in the system comes from theoretical considerations of pro-
tein structure [22,23,16,17,56,57] and also direct experimental ob-
servation. For example, studies with the prototype protein structural 
model for receptors, rhodopsin, indicate the existence of multiple 
conformations when interacting with rhodopsin kinase and arrestin 
[38]. Similarly, fluorescence spectroscopy has furnished evidence 
that the 2-adrenoceptor forms distinct ligand-specific conforma-
tions [18,19,51] while binding and kinetic experiments support 
multiple receptor conformations as well [30,48,49].  
  Heptahelical receptors reside in cell membranes with a series of 
domains facing the extracellular and another series facing the intra-
cellular space. Until the last decade, the primary focus for receptor 
signaling has been heterotrimeric G-proteins. In this regard, there is 
a rich array of signaling possibilities for pleiotropic receptors bind-
ing to numerous types of G-proteins to release alpha and beta-
gamma subunits into the cytosol. However, in the last few years,  
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there have been other receptor partners detected that can react to 
activated receptor and behave as signal sources for the cell. For 
example,  -arrestin, once thought to mediate only receptor inter-
nalization and uncoupling from G-proteins, is now known to act as 
scaffolding for extracellular signal related kinases (ERK’s) to func-
tion as a signaling system in its own right [33,34,53]. In addition, 
numerous other proteins are being discovered that either allow in-
formation to be transmitted into the cell through interaction with 
receptors or couple to receptor to modify the effects of agonists. 
Thus, binding domains on receptors other than those responsible for 
interaction with G-proteins (i.e. PDZ, SH2, SH3 domains) interact 
with various intracellular signaling molecules [5]. Thus the stage is 
set for fine chemical control of the complex heptahelical signaling 
systems for therapeutic advantage; the pharmacological question is, 
how can this be achieved?  
LIGAND CAPABILITY 
  A key to understanding how small druglike molecules can in-
fluence large receptor proteins is the concept of conformational 
selection [6]. This idea describes the binding of a ligand to a range 
of receptor conformations according to its respective affinities for 
each conformation; this stabilizes the bound conformation(s). If 
these conformations are interconvertible, then it will be thermody-
namically favorable for the system to produce more of that confor-
mation at the expense of others, in essence the ligand will cause 
enrichment of its favorite conformation (in accordance with Le 
Chatelier’s principle). If some of these conformations have biologi-
cal activity, then the ligand will confer this biological activity upon 
the system containing the receptor. This can be illustrated with a 
simple example for a system containing two protein states (R and 
R* where the ratio [R*]/[R] is defined by the allosteric constant L):  
               (1) 
  The ligand A binds to R with an affinity KA
-1 and to R* with an 
affinity KA
-1. In the absence of ligand, the ratio of R* as a fraction 
of total receptor species ([Rtotal]= [R] + [R*] + [AR] + [AR*]) is 
given by 0 = L/(1+L) and in the presence of a saturating concentra-
tion of ligand ([A]  ) as  =( (1 + L))/(1 + L). The effect of 
a ligand changing the ratio of R* to R is then given by: 
           (1 + L) 
     =  ----------------              (2) 
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  It can be seen from the condition   1, (the ligand has differ-
ential affinity for the two conformations) that the ratio of the states 
necessarily will change upon ligand binding. The application of this 
concept to more complex systems of multiple conformations leads 
to a similar mechanism for ligand control. Assuming a system of 
conformations R and multiple other conformations labeled Ri where 
i=1 to n controlled by allosteric constants Li to Ln., the fraction of 
receptors not in the R state in the absence of ligand is given by: 
                   (3) 
  The fraction of receptors not in the R state in the presence of a 
saturating concentration of ligand (where the affinity for R is K
-1) 
and for each state Ri as (iK ,)
-1 
             (4) 
  This equation shows that no change in the fraction of receptors 
different from the R state will occur in the presence of the ligand 
only if the affinities of the ligand for every state is the same (equal 
to K, i.e. i to n = 1). In contrast, any differential affinity (i to n  1) 
will result in a change in the ratio of conformational states, i.e. the 
ligand will alter the conformational makeup of the collection. This 
underscores the probability of changes in ensembles with increasing 
conformational states, i.e. the more states there are, the greater the 
probability that a ligand will induce a change.  
MODELING ALLOSTERIC RECEPTOR EFFECTS 
  There have been several models presented to account for and 
quantify allosteric effects on receptors. An allosteric change to a 
receptor essentially produces a new receptor which, in turn, may 
have completely different reactivities toward agonists and antago-
nists. Thus, a model must accommodate all changes to the original 
agonist concentration-response curve (see Fig. 1).  
  One of the earliest and most cited models for allosterism in 
receptors was presented by Ehlert [13]. It describes a receptor that 
can bind a probe molecule A and an allosteric modulator B with 
respective affinities KA
-1 and KB
-1; the affinity of the each is modi-
fied by a factor  when the other is already bound to the receptor: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A sampling of the many possible effects allosteric modulators may have on the concentration-response curve to an agonist. Independent increases or 
decreases in the location parameter and maximal abscissae of these curves as well as incomplete saturable effects (limited shifts of the curve or changes in 
maxima) are possible. In effect, the allosteric modulator theoretically can create a completely new receptor with unique responsiveness to various probes such 
as agonists and/or radioligands. 
Effect of Allosteric Modulators
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                  (5) 
  The allosteric effect is quantified by the cooperativity constant 
 which is the ratio of the affinity of the probe molecule for the 
molecule in the presence and absence of the modulator. For exam-
ple, if =10, then the affinity of the receptor for the probe is in-
creased 10-fold when the modulator is bound. This model, when 
combined with the Operational model for receptor function [4], 
yields a useful model to describe allosteric functional effects (see 
Fig. 2) [25,26]. The amalgam of the Ehlert model and the Opera-
tional model can produce virtually any change in an agonist con-
centration-response curve; the equation for agonist response with 
this model is given by: 
          [A]/KA  (1+[B]/KB) Emax 
Response =-----------------------------------------------------------------             (6) 
      [A]/KA (1 + [B]/KB +  (1 +[B]/KB)) +[B]/KB +1 
where   is the ratio of equilibrium dissociation constants of the 
agonist-receptor complexes (quantifying changes in agonist affin-
ity) and  refers to the ratio of  values (efficacy) of the agonist in 
the particular system in the presence and absence of modulator 
(=’/ where ’ is the efficacy of the agonist in the presence of the 
modulator). Modulator-induced changes in either affinity or effi-
cacy on concentration-response curves to agonists in systems of low 
sensitivity (low receptor density and/or low efficiency of receptor 
coupling) or high sensitivity are shown in Fig. (3).  
  There is no reason to suppose that an allosteric modulator will 
only affect affinity or efficacy of the probe molecule but rather, a 
mixture of effects may result. Under these circumstances, the be-
havior of a concentration-response curve under the influence of a 
modulator may not indicate whether affinity, or efficacy (or both) 
are affected. For example, equation 6 predicts that the location pa-
rameter of the agonist concentration-response curve (EC50) depends 
both upon effects on affinity () and efficacy ().  
                      ( + ) 
Limit Relative Kobs  =   ----------------------------            (7) 
          (1+) 
  Therefore it will not be evident from shifts in the concentration-
response curves whether the modulator affects affinity, efficacy or 
both. However, there are certain conditions and approaches which 
may allow isolation of certain effects. For example, in cases where 
partial agonism is observed it can be shown that changes in the 
maximal response to the agonist are dependent only upon modula-
tor-induced changes in efficacy:  
           (1+) 
Limit Relative Max Resp. =       ---------------               (8) 
          (1 + ) 
  It can also be seen that in cases where the agonist already is 
demonstrating full agonism (high ), modulator-induced changes in 
efficacy may be masked (i.e. for high , Limit Relative Max Resp 
 1; see Fig. 3F and H). A key experimental strategy that can be 
effective is the use of high and low sensitivity assays to assess ef-
fects on agonists. Thus, low receptor density (or low efficiency 
receptor coupled system) may yield systems where the agonist is a 
partial agonist (i.e. produces sub-maximal system maximal re-
sponse). Under these circumstances, pure effects on affinity can be 
separated from those on efficacy by the fact that an affinity effect 
will cause a dextral displacement of the partial agonist curve with 
no change in maxima (see Fig. 3A and C). In contrast, effects on 
efficacy will result in a change in the maximal response of the par-
tial agonist; some of these effects are shown in simulation in Fig. 
(3E) and (G). Similarly, high receptor density (or high efficiency 
receptor coupled system) yield full agonism for most agonists and 
can detect limiting levels of antagonism. As well as being a harbin-
ger of allosteric effect in general, this can also reveal effects on 
efficacy. Specifically, non-zero values of  (efficacy is not zero 
when modulator bound) may be indicated when the modulator fails 
to completely suppress the agonist response (Fig. 3G).  
  Detailed model-driven analyses of allosteric effects have been 
presented elsewhere. An extensive experimental strategy to deline-
ate effects on affinity and efficacy by allosteric modulators based 
on modeling is given by Ehlert [11] where a concise description of 
modulator effects can be obtained through the use of a ‘relative 
activity’ factor. Another model by Hall [20] gives a useful delinea-
tion of allosteric effects on receptor occupancy and activation. This 
model also outlines mechanistically how it may be possible to see 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A simple theoretical model of allosteric receptor function whereby the receptor activates cellular response machinery according to an operational 
equilibrium dissociation constant KE under normal circumstances and with a dissociation constant K’E when bound to the allosteric modulator. 152    Current Neuropharmacology 2007, Vol. 5, No. 3  Terry Kenakin 
dissociation of ligand function and binding. Specifically, an allos-
teric ligand may not affect the overall binding of a ligand (such as 
an agonist) but could block its’ function in terms of producing 
pharmacological response (no effect on  but =0; see Fig. 4). The 
receptor can exist in an inactive ([Ri]) and activated ([Ra]) form, 
both interacting with ligands [A] and [B]. If the radioligand is [A] 
and the allosteric modulator is [B], then a radioligand binding assay 
measures the fraction of total receptor bound to the ligand A (spe-
cies [ARi], [ARa], [ABRa] and [ABRi]) according to the equation 
[20]: 
     [A*]/KA (1 + L + [B]/KB(1 + L)) 
AB = ---------------------------------------------------------------------------------------------- 
       [A*]/KA (1 + L(1 + [B]/KB) + [B]/KB) +L(1 + [B]/KB) + [B]/KB + 1 
                          (9) 
  However, a functional assay measures the fraction of receptor 
species in the activated state ([Ra], [ARa], [BRa] and [ABRa]). Un-
der these circumstances, pharmacological response is given by [20]: 
         [A*]/KA (L(1 + [B]/KB)) + L(1 + [B]/KB) 
f = ----------------------------------------------------------------------------------------------- 
     [A*]/KA (1 + L(1 + [B]/KB) + [B]/KB) +L(1 + [B]/KB) + [B]/KB + 1 
                       (10) 
  Measurement of the different receptor species by binding and 
functional assays accounts for differences that may be seen in bind-
ing and functional effects of allosteric modulators. Referring to Fig. 
(4), an allosteric antagonist with <1 and >1 can demonstrate dis-
sociation between effects on binding and function by reducing the 
active state receptor (due to <1) but increasing the affinity of the 
antagonist-bound receptor for the agonist/radioligand (>1). Under 
these circumstances, functional response will decrease but binding 
of radioligand will be unchanged.  
  A different kind of model has been used to predict receptor 
conformational states. Whereas the previous models are all linkage 
models where the receptor species are defined, this model does not 
define exact conformations but rather discusses probabilities of 
forming different states in response to ligand binding [39,40]. This 
‘probabilistic model’ can be used to calculate the forces controlling 
the macro-affinity of a ligand for a collection of receptor conforma-
tions and also the effects of ligand binding to change the makeup of 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Effects of different modulators on agonist response according to the model depicted in Fig. (2). Changes in affinity () only produce changes in the 
location parameter of the concentration-response curves but no change in maxima. Modulator-induced changes in efficacy () can alter location parameters 
and maximal response. For allosteric potentiation of response, only changes in location are observed for full agonists For partial agonists, changes in maxima 
can be seen. In cases of allosteric reduction in efficacy, both changes in location and maxima may be observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The Hall model [20] of allosteric function whereby the effect of the 
modulator on agonist-induced (A) or spontaneously formed active state 
receptor is affected by binding of the modulator (B). Shaded squares repre-
sent the respective species measured in functional and binding experiments. 
The fact that these species are different for the assay types leaves open the 
possibility that different responses to allosteric modulators may be observed 
in these two different assay formats. 
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that collection of states (efficacy). This theory predicts that there is 
a positive correlation between ligand affinity and efficacy and, this 
was in fact observed in a simulation [28].  
THE IMPLICATIONS OF ALLOSTERISM 
  It can be seen from the foregoing discussion that an allosteric 
modulator can alter the affinity and efficacy of a probe molecule 
(agonist) for a receptor; as noted previously, the receptor essentially 
can become a different receptor with respect to that probe. This has 
implications for the detection and therapeutic use of allosteric 
modulators and also theoretically can give allosteric modulators the 
power to alter large protein-protein interactions. This is because the 
allosterically stabilized receptor may be different from the native 
receptor in a number of regions, not just the binding domain and 
this, in turn, may affect processes that utilize more than one region 
of interaction between the receptor and other proteins. For example, 
blockade of HIV infection is not amenable to single point mutation 
[12]. In fact, mutational studies implicate all four extracellular do-
mains of CCR5 in the process of fusion of the virus with cell mem-
branes [2, 3, 11, 32, 41, 43, 44]. The binding partner in HIV infec-
tion is a viral coat protein gp120 and point mutation studies on this 
protein also indicate that multiple regions of gp120 are involved 
with CCR5-mediated HIV infection [3, 31, 42, 43, 50]. In spite of 
the fact that huge protein-protein interactions mediate HIV entry, 
allosteric modulators such as aplaviroc [8,9] can block this multi-
site interaction with nanomolar potency by stabilizing an allosteric 
conformation of the CCR5 receptor [55]. This serves as a proof of 
concept that the allosteric stabilization of a receptor conformation 
can have powerful effects on the interactions of large proteins.  
  Orthosteric antagonists that block the probe binding site pro-
duce a uniformly unresponsive receptor, i.e. blockade of the recep-
tor with any orthosteric antagonist results in an equally unrespon-
sive receptor. Under these circumstances, the nature of the orthos-
teric antagonist is interchangeable, i.e. as long as the ratio of con-
centration to KB (equilibrium dissociation constant of the antago-
nist-receptor complex) is the same, the pharmacological effect will 
be the same. This is not necessarily true of allosteric modulators. 
For example, aplaviroc, Sch-C and TAK779 are allosteric blockers 
of HIV entry. However, when probed with specific antibodies of 
CCR5, it can be seen that these HIV entry blockers produce differ-
ential binding profiles, i.e. specific probing of the receptor confor-
mation reveals differences in conformation between the allosteri-
cally modified receptors [35]. Thus, with a range of allosteric 
modulators, the allosterically modified receptors may differ from 
each other but be otherwise similar with respect to a function such 
as HIV entry [27]. This may have implications for the development 
of resistance. It is predicted that mutation of HIV is capable of 
overcoming sensitivity to allosteric modification of receptors under 
selective pressure imposed by chronic use of an allosteric antago-
nist [10, 21, 36, 47]. For example, prolonged incubation in vitro 
with the HIV entry inhibitor AD101 leads to resistant strains of 
HIV-1. through an ‘escape mutant’ that is insensitive to blockade 
by this antagonist [54]. However, it would be predicted that these 
resistant strains will be sensitive to another allosteric modulator 
since a different conformation may be presented by a new allosteric 
ligand. In this way, the texture in antagonism imparted to a receptor 
by an allosteric modulator may offer an advantage over orthosteric 
blockers [27].  
  Because an allosteric modulator allows agonist binding to the 
receptor, there can be differences in the resulting effect and allos-
terically-induced texture in antagonism can lead to other interesting 
properties. For example, antagonism can be achieved by either 
blocking affinity (reduce ) but not efficacy (>1), reducing effac-
ing (decreased ) but not affinity (>1), or both. The net result can 
be a complex reflection of activity of the modulator. For exam-
ple,the canonical view of orthosteric antagonism, or antagonism in 
general (decreased  or ) is that the stronger the stimulus, the 
more antagonist is required for blockade. This can be shown by the 
effects of Sch-C on responses to RANTES (Fig. 5A) which reduces 
RANTES efficacy (Watson et al., 2005). However, an interesting 
effect is observed with antagonists that reduce the efficacy of ago-
nists but concomitantly increase the affinity of the receptor for the 
agonist. Fig. (5B) shows the effects of ifenprodil on responses of rat 
cortical neurons to the agonist NMDA. In this case, it can be seen 
that while the maximal response is depressed, the EC50’s of the 
curves actually shift to the left indicating an increase in affinity of 
NMDA receptors for NMDA [29]. An examination of the sche-
matic figure showing the reciprocal effects of modulators and 
probes on receptors (see schematic 5) indicates that, if ifenprodil 
increases the affinity of the receptor for NMDA ( > 1), then NMDA 
will necessarily increase the affinity of the receptor for ifenprodil. 
This means that the probe actually increases the activity of the 
modulator. This can be shown by the inhibition curve of ifenprodil 
calculated in the presence of two concentrations of NMDA (Fig. 6). 
It can be seen that the modulator becomes more potent with increas-
ing agonist concentration [29]. Thus, modulators have the ability to 
adjust their activity according to the magnitude of the signal input, 
a phenomenon referred to as ‘activation-dependent’ blockade.  
 
 
 
 
 
 
 
Fig. (5). Effects of allosteric modulators on agonist response. A. Effect of Sch-C on CCR5-mediated calcium responses to the chemokine RANTES. Curves 
shown in the absence (filled circles) and presence of Sch-C (17.6 nM; filled diamonds : 26.3 nM filled triangles). Open squares indicate half maximal location 
parameters of the curves; note the dextral displacement with antagonsm by Sch-C. B. Blockade of NMDA responses of rat cortical neurons by Ifenprodil. 
Curves shown in the absence (filled circles) nnd presence of ifenprodil (0.1 μM, filled diamonds: 1 μM, filled triangles). Open squares indicate half maximal 
location parameters for the concentration-response curves; note the sinistral displacement with increasing concentrations of ifenprodil. Data redrawn from 
[29]. 154    Current Neuropharmacology 2007, Vol. 5, No. 3  Terry Kenakin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Inhibition of the effects of two concentrations of NMDA (see Fig. 
5) by ifenprodil. It can be seen that the IC50 of ifenprodil for NMDA inhibi-
tion actually decreases with increasing concentrations of NMDA (the   
potency of ifenprodil is greater blocking 100 μM NMDA as compared to 10 
μM NMDA). Data redrawn from [29]. 
  This can be seen from an examination of equation 6 from which 
the following relationship can be derived: 
 IC50       ([A]/KA + 1) 
  ------  =  -------------------              (11) 
 K B     ( [A]/KA + 1) 
  Equation 11 predicts that if the modulator greatly reduces the 
affinity of the receptor for the probe (agonist) (<<1), then the 
denominator  1 and the expression reduces to the Cheng-Prusoff 
correction for simple competitive antagonism [7]. This means that 
the modulator will behave essentially as an orthosteric antagonist; 
whenever a modulator molecule is bound, the affinity of the recep-
tor for the agonist is so low that essentially it is equivalent to an 
orthosteric occlusion of the agonist binding site. However, the in-
teresting aspect of equation 11 is that, if the modulator increases 
the affinity of the agonist for the receptor (>1), then the potency 
of the modulator as a blocker of effect will actually increase with 
increasing agonist concentration (as seen in Fig. 6).  
   It is useful to consider the differences between standard orthos-
teric antagonists (bind to the same site as the receptor probe) and 
allosteric modulators in terms of two important allosteric concepts, 
namely probe dependence and saturation of effect. Probe depend-
ence refers to the fact that a conformational change produced by an 
allosteric modulator can have completely different effects on differ-
ent receptor probes, i.e. a change in shape that is devastating to the 
activity of one probe may have no effect at all (or even produce 
potentiation) on another. For example, the muscarinic receptor al-
lostesric modulator eburnamonine produces a 30-fold potentiation 
of responses to pilocarpine (EC50 for pilocarpine is decreased 30x), 
no change at all to the activity of arecaidine propyl ester and a 15-
fold blockade of the agonist arecoline (EC50 arecoline is decreased 
by a factor of 15) [24]. Saturation of effect reflects the fact that, 
unlike a process such as competition for a common binding site, the 
binding of allosteric modulators to their own site on the receptor 
means that the allosteric effect reaches a maximal asymptote upon 
saturation of the allosteric binding site. Therefore, the allosteric 
effect is finite with a magnitude determined by (in terms of the func-
tional Operational allosteric model) the magnitude(s) of  and . It 
is worth examining the practical consequences of these properties. 
PROBE DEPENDENCE 
  The major implication of this effect is that the physiologically 
relevant probe molecule should be used for all characterizations of 
an allosteric molecule for test data to be predictive therapeutically. 
Effects on a stable laboratory test probe (chosen for practical ex-
perimental reasons) may not be predictive of the natural ligand. 
This idea extends to screening for new allosteric modulators. For 
example, the HIV entry blocker aplaviroc blocks the binding of the 
chemokine ligand 
125I-MIP-1 but does not affect receptor occu-
pancy by the chemokine 
125I-RANTES [35,55]. Therefore, a radio-
ligand displacement screen with 
125I-RANTES would not have 
detected this molecule.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Displacement of bound 
125I-MIP-1 from chemokine C receptors 
type 1 (CCR1) by MIP-1 (filled triangles) and the allosteric ligand 
UCB35625 (open triangles). Incomplete displacement indicates an allosteric 
resetting of the affinity of the receptor for MIP-1. Redrawn from [45]. 
  Another implication of probe dependence is the potential for 
target salvage in cases where a biological target mediates a patho-
logical function and physiologically important and useful functions, 
blockade of that target is contraindicated. However, an allosteric 
modulator has the potential to block the pathological input and 
leave the normal physiological function intact. In cases such as the 
use of the chemokine receptor CXCR4 for HIV entry in late stage 
AIDS [15], this may be important. There are knockout data to sug-
gest that this receptor is functionally important, especially in early 
development [37,52,58]. Therefore, an allosteric modulator that 
blocks the usage of CXCR4 by HIV but leaves the receptor free to 
respond to its natural agonist Stromal Derived Factor 1 (SDF-1) 
would be an advantage. There are intriguing data to show that while 
antagonists of CXCR4 such as the antibody T140 and receptor an-
tagonist AMD3100 both block the chemokine CXCR4 receptor 
mediated signals of the natural agonist SDF-1, they do not block 
the CXCR4-mediated signals of the peptide fragments RSVM and 
ASLW [46].  
  The principle of permissive antagonism is illustrated by the 
HIV blocking properties of aplaviroc. In this case, aplaviroc blocks 
HIV entry but allows the chemokine RANTES to bind unimpeded 
to the receptor. However, this salvage is incomplete in that RAN-
TES function is blocked ( 0.7, =0 equation 6) [55]. In general, 
allosteric modulators give the potential of attacking all biological 
targets that cannot be prosecuted with standard orthosteric mole-
cules.  
  Another important principle associated with allosteric modula-
tors is that of saturation of effect. Fig. (7) shows the inhibition of 
the chemokine 
125I-MIP-1 binding .with non-radioactive MIP-1 
and the small molecule ICB35625. It can be seen that while non-
radioactive MIP-1 reduces the binding of the radioligand to basal 
levels, UCB35625 only produces a 30% reduction in binding [45]. 
This is a classic allosteric effect that reflects a slight reduction in 
affinity produced by the allosteric modulator. Effectively, such 
antagonists will reduce but not completely block physiological Allosteric Theory: Taking Therapeutic Advantage  Current Neuropharmacology, 2007, Vol. 5, No. 3    155 
response, a unique effect that may be therapeutically useful in cer-
tain pathological conditions.  
CONCLUSIONS 
  It can be seen that the promiscuous nature of 7 transmembrane 
receptors, with respect to coupling proteins in the cell membrane 
and in association with their allosteric nature, allows them to form 
different conformations, and this can produce a potentially sophisti-
cated signaling system. The challenge now is to harness this sophis-
tication through selective ligands to yield therapeutically useful 
profiles of drug activity. The key to this process is to have the eyes 
to see specific receptor behaviors, i.e. to have a range of assays 
capable of observing different aspects of receptor activity. In addi-
tion, theoretical models that describe and predict these effects are 
useful as indicators of the implications of the effects observed ex-
perimentally.  
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